ScholarLens Back to search
2005•Journal of Clinical HematologyRequires access

Clinical efficacy of thalidomide with melphalan and prednison in the treatment of 23 cases multiple myeloma

Zheng Cuiping

Open publisher page 0 citations

Abstract

Objective:To report the preliminary result of therapy with thalidomide in 23 cases of multiple myeloma(MM) patients.Method:The initial dose of thalidomide was 100 mg/d, then increased 50 mg/d to 400 mg/d every week until the patient's maximal tolerance. Chemotherapy with melphalan 0.1 mg/kg daily and oral prednison 1.0 mg/kg daily for seven days was accompanied in all patients.Result:Among the 23 patients 16 achieved partial remission (PR), 4 improved and 3 had no effect.Conclusion:Thalidomide can be used in the treatment of MM. Side effects was tolerable.

About this research paper

What this paper is about

Objective:To report the preliminary result of therapy with thalidomide in 23 cases of multiple myeloma(MM) patients.Method:The initial dose of thalidomide was 100 mg/d, then increased 50 mg/d to 400 mg/d every week until the patient's maximal tolerance. Chemotherapy with melphalan 0.1 mg/kg daily and oral prednison 1.0 mg/kg daily for seven days was accompanied in all patients.Result:Among the 23 patients 16 achieved partial remission (PR), 4 improved and 3 had no effect.Conclusion:Thalidomide can be used in the treatment of MM. Side effects was tolerable.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To report the preliminary result of therapy with thalidomide in 23 cases of multiple myeloma(MM) patients.Method:The initial dose of thalidomide was 100 mg/d, then increased 50 mg/d to 400 mg/d every week until the patient's maximal tolerance. Chemotherapy with melphalan 0.1 mg/kg daily and oral prednison 1.0 mg/kg daily for seven days was accompanied in all patients.Result:Among the 23 patients 16 achieved partial remission (PR), 4 improved and 3 had no effect.Conclusion:Thalidomide can be used in the treatment of MM. Side effects was tolerable.

Key concepts: Thalidomide, Melphalan, Medicine, Multiple myeloma, Chemotherapy, Internal medicine, Gastroenterology, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical efficacy of thalidomide with melphalan and prednison in the treatment of 23 cases multiple myeloma — Research Paper | ScholarLens